版本:
中国

BRIEF-Ampio says met with FDA for Ampion biological license

Sept 29 Ampio Pharmaceuticals Inc:

* Ampio updates clinical and regulatory activity

* Has met with CBER division of FDA to seek guidance on best path forward to obtain a biological license for Ampion

* Reported completion of enrollment for AP-011 sudy to evaluate safety of single intra-articular injection of Ampion for basal thumb arthritis Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐